Tempus Acquires Personalis for $1.5 Billion to Expand Cancer Testing Capabilities
Tempus, an AI diagnostics company, has agreed to acquire Personalis in a $1.5 billion deal to gain full control of the NeXT Personal cancer test that detects minimal residual disease (MRD). Despite Wall Street's strategic approval, Tempus' stock price dropped following the announcement.
Topics: AI cancer testing diagnostics healthcare